AI Article Synopsis
- The study investigated risk factors for complications and long-term outcomes in patients aged 80 and above who underwent surgery for gastric cancer between 2013 and 2020.
- Out of 109 patients, 26.6% experienced postoperative complications, which were significantly linked to higher blood loss during surgery.
- Key findings indicated that reducing blood loss during operations can lessen complications, and both postoperative complications and low nutritional status can negatively affect long-term survival rates.
Article Abstract
Background/aim: We aimed to assess the risk factors for postoperative complications and long-term outcome of patients aged ≥80 years after curative resection for gastric cancer (GC).
Patients And Methods: Patients aged ≥80 years who underwent curative gastrectomy for stage I-III GC between 2013 and 2020 were included. Clinical factors were retrospectively analyzed.
Results: Of all 109 patients, 29 (26.6%) had 33 postoperative complications (Clavien-Dindo grade ≥2). The rate of postoperative complications was higher in those with greater blood loss (≥170 ml, p<0.001). In multivariate analysis, greater blood loss was confirmed as an independent predictor of postoperative complications (p<0.001). The 30-day, 180-day, 1-year, and 3-year cumulative overall survival rates were 100%, 97.0%, 91.6%, and 74.7%, respectively. Multivariate analysis showed postoperative complications (p=0.014) and low prognostic nutritional index (PNI, p=0.044) were independent prognostic factors for poor overall survival.
Conclusion: Performing operations with less bleeding is important to reduce postoperative complications. According to the analysis of long-term survival, patients who experience postoperative complications and patients with a low preoperative PNI require special attention in the follow-up period. Nutritional support should be considered in patients with malnutrition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962803 | PMC |
| http://dx.doi.org/10.21873/cdp.10095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trimetazidine as an adjunct to standard hydration reduces the incidence of contrast-induced acute kidney injury in patients with renal insufficiency undergoing coronary angiography or percutaneous cardiac intervention: a systematic review and meta-analysis.
BMC Nephrol
December 2024
Department of Nephrology, Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Background: Contrast-induced acute kidney injury (CI-AKI) is a known complication after coronary angiography (CAG) or percutaneous coronary intervention (PCI). Clinical evidence suggests that trimetazidine (TMZ), an anti-ischemic drug, may prevent CI-AKI. We aimed to evaluate the role of trimetazidine in preventing CI-AKI in patients with pre-existing renal dysfunction undergoing CAG or PCI.
View Article and Find Full Text PDFTranslation and psychometric validation of the Heart Failure Symptom Tracker (HFaST).
BMC Cardiovasc Disord
December 2024
NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, REAL, CCAL, NOVA University Lisboa, Lisbon, Portugal.
Background: Heart Failure (HF) is a global public health issue with high morbidity and mortality rates. Symptom management improves HF patients' quality of life and demonstrates a potential reduction in hospitalisation, particularly among individuals aged 65 and over. Early identification of patients at higher risk of hospitalisation is essential to guide patient-centred interventions.
View Article and Find Full Text PDFAssociation of timed up and go test results with future injurious falls among older adults by sex: a population-based cohort study.
BMC Geriatr
December 2024
Red Cross College of Nursing, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, 06974, Korea.
Background: This study aimed to determine whether sex-specific timed up and go (TUG) test results are associated with injurious fall occurrence in older adults and to identify risk factors for injurious falls based on TUG test results.
Methods: Data were obtained from an older adult cohort database provided by the National Health Insurance Service, which included 34,030 individuals aged 66 years or older who underwent life-transition health examinations in 2007 and 2008 and were followed up until 2019. To identify the risk factors for injurious falls, this study performed a Cox proportional hazard regression analysis by sex, with individual characteristics, including TUG test results, as independent variables.
Exploring Congruence Between Patient and Clinician Expectations of Benefit in the Non-Surgical Management of Common Musculoskeletal Conditions in Tertiary Care.
Musculoskeletal Care
December 2024
Physiotherapy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Background: Patient and clinician expectations of benefit from recommended management approaches may potentially impact the success of managing musculoskeletal conditions.
Methods: This was a multisite study in an advanced practice musculoskeletal service across Queensland, Australia. Relationships between patient and clinician (advanced physiotherapy practitioner) expectations of benefit, patient characteristics, and clinical outcome recorded 6 months later were explored with regression analysis in 619 patients undergoing non-surgical multidisciplinary care for either knee osteoarthritis (n = 286), low back pain (n = 249) or shoulder impingement syndrome (n = 84).
Arimoclomol: First Approval.
Drugs
December 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Arimoclomol (MIPLYFFA™), an oral small molecule that crosses the blood brain barrier and is thought to upregulate CLEAR (Coordinated Lysosomal Expression and Regulation) network genes and improve lysosomal function, is being developed by Zevra Therapeutics Inc., for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). In September 2024, arimoclomol was approved for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older in the USA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!